Compare ASTRAZENECA PHARMA with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ALEMBIC PHARMA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA ALEMBIC PHARMA ASTRAZENECA PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 129.7 16.8 773.9% View Chart
P/BV x 36.4 6.7 546.6% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ASTRAZENECA PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
ALEMBIC PHARMA
Mar-19
ASTRAZENECA PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs1,278664 192.5%   
Low Rs883412 214.0%   
Sales per share (Unadj.) Rs228.4208.7 109.4%  
Earnings per share (Unadj.) Rs10.431.0 33.4%  
Cash flow per share (Unadj.) Rs16.337.1 43.8%  
Dividends per share (Unadj.) Rs05.50 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs98.8144.2 68.5%  
Shares outstanding (eoy) m25.00188.52 13.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.72.6 183.4%   
Avg P/E ratio x104.217.4 600.3%  
P/CF ratio (eoy) x66.414.5 458.1%  
Price / Book Value ratio x10.93.7 293.1%  
Dividend payout %017.7 0.0%   
Avg Mkt Cap Rs m27,008101,461 26.6%   
No. of employees `0001.4NA-   
Total wages/salary Rs m1,5357,467 20.6%   
Avg. sales/employee Rs Th4,210.9NM-  
Avg. wages/employee Rs Th1,132.2NM-  
Avg. net profit/employee Rs Th191.1NM-  
INCOME DATA
Net Sales Rs m5,71039,347 14.5%  
Other income Rs m12394 130.6%   
Total revenues Rs m5,83339,441 14.8%   
Gross profit Rs m4638,736 5.3%  
Depreciation Rs m1471,152 12.8%   
Interest Rs m0184 0.0%   
Profit before tax Rs m4387,493 5.8%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1791,568 11.4%   
Profit after tax Rs m2595,844 4.4%  
Gross profit margin %8.122.2 36.5%  
Effective tax rate %40.820.9 195.3%   
Net profit margin %4.514.9 30.6%  
BALANCE SHEET DATA
Current assets Rs m3,20919,577 16.4%   
Current liabilities Rs m2,07014,896 13.9%   
Net working cap to sales %20.011.9 167.8%  
Current ratio x1.61.3 118.0%  
Inventory Days Days7290 80.6%  
Debtors Days Days3545 77.0%  
Net fixed assets Rs m79027,097 2.9%   
Share capital Rs m50377 13.3%   
"Free" reserves Rs m2,41926,811 9.0%   
Net worth Rs m2,46927,188 9.1%   
Long term debt Rs m04,993 0.0%   
Total assets Rs m4,60547,778 9.6%  
Interest coverage xNM41.7-  
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x1.20.8 150.6%   
Return on assets %5.612.6 44.6%  
Return on equity %10.521.5 48.8%  
Return on capital %17.723.6 75.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30019,453 1.5%   
Fx outflow Rs m2,0156,065 33.2%   
Net fx Rs m-1,71513,388 -12.8%   
CASH FLOW
From Operations Rs m888,120 1.1%  
From Investments Rs m-94-7,556 1.2%  
From Financial Activity Rs mNA590 0.0%  
Net Cashflow Rs m-61,153 -0.5%  

Share Holding

Indian Promoters % 0.0 74.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 2.9 10.3%  
FIIs % 15.7 9.1 172.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 13.9 65.5%  
Shareholders   12,856 49,328 26.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   NOVARTIS  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  IPCA LABS  NATCO PHARMA  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 25, 2021 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS